Socioecological factors linked with pharmaceutical incentive-driven prescribing in Pakistan

Pharmaceutical marketing through financial incentivisation to general practitioners (GPs) is a poorly studied health system problem in Pakistan. Pharmaceutical incentivisation is seen to be distorting GPs prescribing behaviour that can compromise the health and well-being of patients. We draw on a conceptual framework outlined in the ecological system theory to identify multiple factors linked with pharmaceutical incentivisation to GPs in Pakistan. We conducted qualitative interviews with 28 policy actors to seek their views on the health system dynamics, how they sustain pharmaceutical incentivisation and their effect on the quality of care. Our analysis revealed four interlinked factors operating at different levels and how they collectively contribute to pharmaceutical incentivisation. In addition to influences such as the increasing family needs and peers’ financial success, sometimes GPs may naturally be inclined to maximise incomes by engaging in pharmaceutical incentivisation. On other hand, the pharmaceutical market dynamics that involve that competition underpinned by a profit-maximisation mindset enable pharmaceutical companies to meet GPs’ desires/needs in return for prescribing their products. Inadequate monitoring and health regulations may further permit the pharmaceutical industry and GPs to sustain the incentive-driven relationship. Our findings have important implications for potential health reforms such as introducing regulatory controls, and appropriate monitoring and regulation of the private health sector, required to address pharmaceutical incentivisation to GPs

Business · Economics · Environmental health · Incentive · Public economics · Healthcare Systems and Reforms · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare

• Uncertainties about the quality of medical products globally

  Open Access•Patricia Kingori, Koen Peeters Grietens et al.•BMJ Global Health•2023

  Incluir item

• Doctors taking bribes from pharmaceutical companies is common and not substantially reduced by an educational intervention

  Open Access•Mishal Khan, Muhammad Naveed Noor et al.•BMJ Global Health•2024

  Incluir item

• National action on antimicrobial resistance and the political economy of health care

  Open Access•Mirko Heinzel, Mathias Koenig-Archibugi•Journal of European Public Policy•2024

  Incluir item

• Healthcare consumers’ perceptions of incentive-linked prescribing

  Open Access•Muhammad Naveed Noor, Haider Safdar Abbasi et al.•PLOS Global Public Health•2024

  Incluir item

• Corporatization and the Social Transformation of Doctoring

  Open Access•John B Mckinlay, John D Stoeckle•International Journal of Health…•1988

  Incluir item

• Improving antibiotic use through behaviour change

  Open Access•Carla Cuevas, Neha Batura et al.•Health Policy and Planning•2021

  Incluir item

• Real time surveillance of Covid-19 space and time clusters during the summer 2020 in Spain

  Open Access•Nicolás Rosillo, Javier Del-Águila-Mejía et al.•BMC Public Health•2021

  Incluir item

• Community pharmacies, drug stores, and antibiotic dispensing in Indonesia

  Open Access•Astri Ferdiana, Marco Liverani et al.•BMC Public Health•2021

  Incluir item

• What are the barriers to implementing national antimicrobial resistance action plans? A novel mixed-methods policy analysis in Pakistan

  Open Access•Mishal Khan, Mishal S Khan et al.•Health Policy and Planning•2020

  Incluir item

• Defining quality of care

  Open Access•M Campbell, Stephen Campbell et al.•Social Science & Medicine•2000

  Incluir item

• The healthcare field as a marketplace

  Muhammad Naveed Noor, Marco Liverani et al.•Health Sociology Review•2023

  Incluir item